Sinequan

Insomnia, Neurotic depression, Depression + 8 more

Treatment

20 Active Studies for Sinequan

What is Sinequan

Doxepin

The Generic name of this drug

Treatment Summary

Doxepin is a drug prescribed to treat depression, anxiety, and insomnia. It is a type of medication known as a tertiary amine that helps to balance the levels of certain chemicals in the brain. Doxepin was first approved by the FDA in 1969 for the treatment of depression and later approved for the treatment of insomnia in 2010. It belongs to the same drug family as amitriptyline, clomipramine, desipramine, imipramine, nortriptyline, protriptyline, and trimipramine.

Sinequan

is the brand name

image of different drug pills on a surface

Sinequan Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Sinequan

Doxepin

1969

307

Effectiveness

How Sinequan Affects Patients

Doxepin is a type of antidepressant that works by decreasing the activity of the brain. It can also help with insomnia and anxiety. It may take two weeks for the antidepressant effects to show, but the sedative effects are immediate. At high doses, it can cause central nervous system depression and its anticholinergic and antiadrenergic effects can limit its efficacy.

How Sinequan works in the body

Doxepin works by blocking histamine receptors in the skin to reduce inflammation. It also works on the central nervous system to increase levels of serotonin and norepinephrine. This helps improve mood and reduce depression symptoms. Doxepin may also desensitize serotonin 1A receptors and beta-adrenergic receptors. It is believed to increase dopamine transmission in the frontal cortex which is thought to help improve mood.

When to interrupt dosage

The advocated dose of Sinequan is contingent upon the determined condition, for example Depression, Involutional, Mental Disorder, Organic and Insomnia. The dose can be found in the table below, based on the technique of delivery (e.g. Oral or Tablet - Oral).

Condition

Dosage

Administration

Insomnia

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Neurotic depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Generalized Anxiety Disorder

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Neuropathic Pain

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Itching

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Behcet Syndrome

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Alcoholism

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Neurodermatitis

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

Sinequan has four contraindications and thus should not be taken when encountering any of the conditions shown in the following table.

Sinequan Contraindications

Condition

Risk Level

Notes

untreated narrow angle glaucoma

Do Not Combine

Pulse Frequency

Do Not Combine

Urinary Retention

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Doxepin may interact with Pulse Frequency

There are 20 known major drug interactions with Sinequan.

Common Sinequan Drug Interactions

Drug Name

Risk Level

Description

4-Methoxyamphetamine

Major

Doxepin may increase the vasopressor activities of 4-Methoxyamphetamine.

Acepromazine

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Doxepin is combined with Aclidinium.

Alfuzosin

Major

Doxepin may increase the hypotensive activities of Alfuzosin.

Aripiprazole

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

Sinequan Toxicity & Overdose Risk

Doxepin is toxic in high doses, with a lethal dose of 180mg/kg in mice and 147mg/kg in rats. Overdosing on doxepin can cause seizures, heart rhythm problems, loss of consciousness, low blood pressure, central nervous system depression, changes on an EKG, and even death. In fertility studies, doxepin was found to reduce the time of copulation, decrease the number of viable embryos, decrease litter size, and decrease sperm motility. There is no evidence that doxepin causes cancer or mutations.

image of a doctor in a lab doing drug, clinical research

Sinequan Novel Uses: Which Conditions Have a Clinical Trial Featuring Sinequan?

1020 active trials are being conducted to assess the potential of Sinequan in managing Generalized Anxiety Disorder, Atopic Dermatitis and Bipolar Disorder.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

169 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3, Phase 1

Depressive Disorder, Major

0 Actively Recruiting

Insomnia

0 Actively Recruiting

Depression

281 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Alcoholism

7 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Neurotic depression

0 Actively Recruiting

Depressive Disorder, Major

0 Actively Recruiting

Itching

3 Actively Recruiting

Phase 3, Not Applicable

Behcet Syndrome

1 Actively Recruiting

Not Applicable

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Neurodermatitis

0 Actively Recruiting

Sinequan Reviews: What are patients saying about Sinequan?

5

Patient Review

8/30/2010

Sinequan for Itching

This medication has been a lifesaver for me on two different occasions when I've suffered from chronic urticaria. It's completely alleviated my problem when taken with other OTC antihistamines. I only need to take 10 mg each night for 3-4 weeks during flare-ups now. The main side effects I've experienced are dry mouth and an extreme drop in libido due to decreased lubrication.

5

Patient Review

1/17/2018

Sinequan for Nerve Pain

My neurologist prescribed this for me 15 years ago when I was 50 and suffering from peripheral neuropathy pain. It's been a godsend, allowing me to walk without pain.

4.7

Patient Review

7/29/2016

Sinequan for Anxiousness associated with Depression

Doxepin has been a game-changer for me. It's helped with my anxiety, depression, and insomnia. I have experienced dry mouth as a side effect; however, it hasn't been bad enough to make me want to stop taking the medication.

4.3

Patient Review

5/1/2010

Sinequan for Anxiousness associated with Depression

Sinequan has been an utter game-changer for me. I was struggling with anxiety and depression to the point where I rarely left my house, but this medication helped me get my life back. The only downside is that I've gained about 30 pounds since starting it.

3.7

Patient Review

10/8/2011

Sinequan for Anxious

This medication didn't do much for my constipation.

3

Patient Review

11/2/2011

Sinequan for Depression

I started taking this treatment two weeks ago. So far, I haven't seen a huge difference, but it takes time for medications to build up in your system so I'm hopeful.

2.3

Patient Review

9/24/2013

Sinequan for Depression

I'm still struggling with depression, and this medication hasn't been helping.

1.7

Patient Review

3/16/2014

Sinequan for Depression

This didn't help me at all and I had a lot of trouble sleeping.

1

Patient Review

3/26/2010

Sinequan for Bipolar Depression

The side effects of this medication were really terrible. I gained a lot of weight, felt groggy and irritable the next day, and would wake up in the middle of the night and eat everything in sight. I stopped taking it after only 8 months because it was making me so unhealthy.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sinequan

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How much sinequan can you take for sleep?

"Adults should take 6 milligrams (mg) of the medication once a day. Older adults should take 3 mg of the medication once a day. The doctor may adjust the dose as needed."

Answered by AI

Is sinequan still prescribed?

"The brand name Sinequan is no longer available in the United States. However, generic forms are still available."

Answered by AI

What is the drug sinequan used for?

"This medication is used to improve mood, relieve tension and anxiety, help with sleep, and increase energy. It belongs to a class of medications called tricyclic antidepressants."

Answered by AI

Is doxepin a good sleeping pill?

"This results in improvement in depression or anxiety.

Doxepin is used to treat anxiety or depression and also to treating insomnia by increasing levels of certain chemicals in the brain, which improves depression or anxiety."

Answered by AI

Clinical Trials for Sinequan

Image of Northwestern University in Evanston, United States.

Sleep and Dreaming Practices for Anxiety

18+
All Sexes
Evanston, IL

People spend approximately one-third of their lives asleep, yet sleep is often underused as an opportunity to support psychological well-being. Contemplative traditions, including Tibetan Dream Yoga, have developed practices that use waking imagination and lucid dreaming to explore perception, awareness, and habitual patterns of thinking. Recent advances in sleep monitoring, dream communication, and lucid dream induction now make it possible to study these practices using scientific methods. This study is a randomized controlled trial designed to examine the feasibility and effects of a Dream-Yoga-inspired intervention compared with an active control condition. The intervention combines waking and dreaming practices that are adapted for individuals without prior experience and delivered using virtual reality-based training and home sleep technology. The program is designed to be scalable and culturally neutral, without requiring prior knowledge of contemplative or religious traditions. The primary goals of the study are to characterize sleep and waking neurophysiology associated with Dream-Yoga-inspired practices and to evaluate whether participation is associated with changes in sleep-related brain activity and cognitive processes. Outcomes include measures of lucid dreaming, sleep physiology, and waking cognitive and perceptual processes. Anxiety will be assessed as an exploratory outcome to examine whether participation may be associated with changes in emotional experience. This study is not designed to provide treatment for anxiety or other clinical conditions. Results from this study will help inform the development of scalable sleep-based mental training approaches and guide future research on the use of dreaming and sleep practices to support psychological health and well-being

Phase < 1
Waitlist Available

Northwestern University (+1 Sites)

Image of University of Michigan in Ann Arbor, United States.

Virtual Reality for Depression in Multiple Sclerosis

18+
All Sexes
Ann Arbor, MI

This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems. The study hypotheses include: * The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions. * The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.

Recruiting
Has No Placebo

University of Michigan

Hala Darwish, PhD

Apple Inc.

Have you considered Sinequan clinical trials?

We made a collection of clinical trials featuring Sinequan, we think they might fit your search criteria.
Go to Trials
Image of Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry in Charleston, United States.

Mindfulness Training for Depression

18 - 70
All Sexes
Charleston, SC

This NIH-funded single-arm pilot tests the feasibility, acceptability, and preliminary effects of embedding brief guided mindfulness practice (via the Healthy Minds smartphone app) into the inter-session intervals of clinically administered accelerated intermittent theta-burst stimulation (aiTBS) for major depressive disorder (MDD). Participants receive aiTBS as standard clinical care at MUSC; the research intervention is daily guided mindfulness practice during the aiTBS course. Outcomes include feasibility/acceptability, changes in state mindfulness and hedonic tone (Day 0 to Day 5), perceived ease of meditation, trait mindfulness at 4 and 12 weeks, and durability of antidepressant response (PHQ-9) at 4 and 12 weeks.

Waitlist Available
Has No Placebo

Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry

Clayton Olash, MD

Have you considered Sinequan clinical trials?

We made a collection of clinical trials featuring Sinequan, we think they might fit your search criteria.
Go to Trials
Image of Worcester Recovery Center and Hospital in Worcester, United States.

Changing Lives and Changing Outcomes-9 for Serious Mental Illness

18+
All Sexes
Worcester, MA

People with serious mental illness (depression, bipolar, and schizophrenia spectrum disorders) have high rates of repeated criminal legal involvement and psychiatric hospitalizations. Longstanding research shows that in addition to treating clients' symptoms of mental illness, targeting risk factors for legal involvement can help reduce their chances of future incarcerations. Because hospitals are becoming increasingly forensic, treatment programs that address both mental illness and risk factors for legal involvement may be especially helpful in a state hospital setting, like Worcester Recovery Center and Hospital (WRCH). This treatment study offers an adjunctive 9-session intervention, Changing Lives and Changing Outcomes-9 (CLCO-9), for patients at WRCH; this program is designed to help people with serious mental illness who are involved in the legal system increase their awareness of their mental health and reduce their chances of future legal involvement. The investigators are proposing a treatment study testing the use of the CLCO-9 group intervention with patients with serious mental illness with current or previous criminal legal involvement at Worcester Recovery Center and Hospital (WRCH). The study has three aims: 1. Evaluate feasibility, fidelity, and patient satisfaction during the implementation of the CLCO-9 group treatment at WRCH 2. Evaluate CLCO-9's effectiveness on improving patient's self-reported mental health, and behavioral indicators of mental health and risk factors for legal involvement 3. Explore changes in WRCH clinicians' knowledge and attitudes about treating risk factors for criminal legal involvement. To test these aims, the research team will employ a two-phase study. In the first phase, the researchers will implement the intervention and make necessary adjustments to maximize the success of the implementation. In the second phase, the researchers will evaluate the treatment program's effectiveness in producing change from pre- to post-treatment. All patient participants in this study will receive the intervention. The projected sample size is about 20 treatment completers and 4 to 8 group leaders.

Waitlist Available
Has No Placebo

Worcester Recovery Center and Hospital

Faith Scanlon, PhD

Have you considered Sinequan clinical trials?

We made a collection of clinical trials featuring Sinequan, we think they might fit your search criteria.
Go to Trials